Modeling red blood cell survival data

被引:0
作者
Julia Korell
Frederiek E. Vos
Carolyn V. Coulter
John B. Schollum
Robert J. Walker
Stephen B. Duffull
机构
[1] University of Otago,School of Pharmacy
[2] University of Otago,Department of Medicine, Dunedin School of Medicine
来源
Journal of Pharmacokinetics and Pharmacodynamics | 2011年 / 38卷
关键词
Red blood cells; Lifespan; Random destruction; Senescence; Radioactive chromium; Chronic kidney disease; Hemodialysis; Two-stage approach; Population approach; MONOLIX;
D O I
暂无
中图分类号
学科分类号
摘要
Anaemia of chronic kidney disease (CKD) is a common complication in patients with renal impairment, especially in end-stage renal failure. As well as erythropoietin deficiency, decreased red blood cell survival is a contributing factor. However, it remains unclear which mechanism underlies the altered survival of red blood cells (RBCs). In this work a previously developed statistical model for RBC survival was applied to clinical data obtained from 14 patients with CKD undergoing hemodialysis as well as 14 healthy controls using radioactive chromium (51Cr) as random labelling method. A classical two-stage approach and a full population analysis were applied to estimate the key parameters controlling random destruction and senescence in the model. Estimating random destruction was preferred over estimating an accelerated senescence in both approaches and both groups as it provided the better fit to the data. Due to significant nonspecific random loss of the label from the cells that cannot be quantified directly only a relative RBC survival can be obtained from data using 51Cr as labelling method. Nevertheless, RBC survival was found to be significantly reduced in CKD patients compared to the controls with a relative reduction of 20–30% depending on the analysis method used.
引用
收藏
页码:787 / 801
页数:14
相关论文
共 108 条
[11]  
Wasserman B(1987)Erythropoietin and anemia in chronic renal failure Exp Hematol 15 785-789
[12]  
Leiserowitz M(1953)The use of radioactive chromium 51 as an erythrocyte tagging agent for the determination of red cell survival in vivo J Clin Invest 29 1260-1276
[13]  
Eschbach J(1980)Recommended method for radioisotope red-cell survival studies Br J Haematol 45 659-666
[14]  
Funk D(1997)The NUBASE evaluation of nuclear and decay properties Nucl Phys A 624 1-124
[15]  
Adamson J(1963)The red cell chromium elution rate in patients with some hematologic diseases Blood 21 63-69
[16]  
Kuhn I(1953)Radioactive sodium chromate for the study of survival of red blood cells: I. The effect of radioactive sodium chromate on red cells J Lab Clin Med 42 358-367
[17]  
Scribner B(2003)Hemoglobin loss from erythrocytes in vivo results from spleen-facilitated vesiculation Blood 101 747-751
[18]  
Finch C(2007)Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO) J Pharmacokinet Pharmacodyn 34 849-868
[19]  
Loge J(1980)REDCE: a computer program for the analysis of red cell survival data Comput Programs Biomed 12 172-182
[20]  
Lange R(2008)Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep J Pharmacokinet Pharmacodyn 35 285-323